2024-08-01T16:05:26-05:00 2023-12-31 PwC US Tax LLP 655 NEW YORK AVENUE NW STE 1100 WASHINGTON DC 20001 990 2023-01-01 473355381 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY % SARA COBLIN PARK 4159304386 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 MICHAEL POLANSKY EXEC. VP 4159304386 2024-08-31 true true TRAVIS PATTON P00369623 6464713000 2023 2024-08-08 14:25:15Z SEAN PARKER 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 62092135 false X WWW.PARKERICI.ORG X 2015 CA SEE SCHEDULE O 16 14 49 19 0 0 691633 1204708 13501237 8658418 15719892 12348436 2856375 1451074 32769137 23662636 18087363 14807382 0 0 20762093 11068299 0 0 263698 23392196 17027670 62241652 42903351 -29472515 -19240715 307154607 255027743 57635216 52813770 249519391 202213973 X THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY'S (PICI) MISSION IS TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TURN ALL CANCERS INTO CURABLE DISEASES. false false 37697468 14807382 8658418 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI CONDUCTS ITS OWN RESEARCH AND CLINICAL TRIALS AND PROVIDES ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM. 37697468 true true false false false false false false false false true true true false true true true false false false true false false false false false false true false true false false false true false false false false false false false false true true false false false true 42 0 true 49 true false false false false false false false false false false false false X 16 14 true false false false false true true true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X SARA COBLIN 6288997600 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 X UTE DUGAN MD CHIEF MEDICAL OFFICER 40.0 0.0 X 789156 0 55067 JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 40.0 0.0 X 763765 0 53749 KEVIN MARKS CHIEF LEGAL OFFICER 40.0 0.0 X 559373 0 114899 TARAK MODY CHIEF BUSINESS OFFICER 40.0 0.0 X 614960 0 54899 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 40.0 0.0 X 547440 0 41286 SARA COBLIN SR VP FINANCE & ADMIN. 40.0 0.0 X 548044 0 38646 MARKO SPASIC SR MEDICAL DIR, HEAD OF MED 40.0 0.0 X 476280 0 15180 CHRIS CABANSKI SR DIR, NETWORK CLINICAL RES. 40.0 0.0 X 355867 0 41334 SEAN N PARKER CHAIR OF THE BOARD & DIRECTOR 5.0 5.0 X X 0 0 0 MICHAEL POLANSKY EXECUTIVE VP & DIRECTOR 5.0 5.0 X X 0 0 0 TOM VAN LOBEN SELS TREASURER & DIRECTOR 1.0 0.0 X X 0 0 0 JEFFREY A BLUESTONE PHD VICE CHAIR & DIRECTOR 1.0 0.0 X 0 0 0 TONY COLES MD DIRECTOR 1.0 0.0 X 0 0 0 ERIC ESRAILIAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 SCOTT GOTTLIEB MD DIRECTOR 1.0 0.0 X 0 0 0 BEN HOROWITZ DIRECTOR 1.0 0.0 X 0 0 0 JEFF HUBER DIRECTOR 1.0 0.0 X 0 0 0 BOB HUGIN DIRECTOR 1.0 0.0 X 0 0 0 REED JOBS DIRECTOR 1.0 0.0 X 0 0 0 JOEL MARCUS DIRECTOR THRU 3/23 0.25 0.0 X 0 0 0 BOB NELSEN DIRECTOR 1.0 0.0 X 0 0 0 BRUCE PARKER PHD DIRECTOR 1.0 0.0 X 0 0 0 BOB PITTMAN DIRECTOR 1.0 0.0 X 0 0 0 RAMY IBRAHIM MD DIRECTOR 1.0 0.0 X 0 0 0 MARGO GEORGIADIS DIRECTOR 1.0 0.0 X 0 0 0 SUSAN DAWSON SECRETARY 5.0 5.0 X 0 0 0 4654885 0 415060 32 false true false LUMA BRIDGE 1305 EAST HOUSTON STREET SAN ANTONIO TX 78205 CLINICAL TRIAL EXP 2402357 REGENTS OF UNIV OF CAL SAN FRANC PO BOX 748872 LOS ANGELES CA 90074 PATENT/CLINIC EXP. 723631 THE TRUSTEES OF THE UNIV OF PA 3451 WALNUT ST 5TH FL FRANKLIN B PHILADELPHIA PA 19104 TEST/VALIDATION EXP. 633217 CLINVERSE-CLINPAY PO BOX 419473 BOSTON MA 02241 CLINICAL TRIAL EXP 599732 THE REGENTS OF THE UNIV OF CALIFOR 1111 FRANKLIN STREET 11TH FLOOR OAKLAND CA 94607 PATENT EXPENSES 544364 29 1204708 1204708 RESEARCH STUDY SPONSORSHIP 900099 4558847 4558847 LICENSE FEES 900099 4099571 4099571 8658418 5346695 5346695 0 1451074 1451074 0 0 0 45431240 38429499 7001741 7001741 7001741 0 0 0 0 0 0 0 0 0 0 23662636 8658418 13799510 14807382 14807382 0 0 0 0 2248427 1661737 586690 0 7587904 5602342 1878529 107033 139902 96764 40661 2477 580620 346874 220517 13229 511446 360729 147329 3388 0 2050912 1726663 324249 396281 396281 0 0 0 1670313 1465373 203527 1413 41452 23346 18106 134831 38922 94848 1061 1068568 881457 155077 32034 0 1505114 933171 556892 15051 783088 732450 40702 9936 0 2997816 2927740 21822 48254 0 0 409412 409412 214185 20636 193549 INSTITUTION STAFF SUPPORT 1444079 1444079 0 0 BIOBANKING 440949 440949 0 0 CLINICAL TRIAL SUPPORT 3111654 3111654 0 0 TESTING VALIDATION 540600 540600 0 0 218416 148534 58166 11716 42903351 37697468 4942185 263698 6165490 3286878 107152164 65585234 0 0 3976058 4756494 0 764842 0 0 0 0 0 0 2444972 2651610 8961523 8706523 409412 255000 0 0 17939587 23331587 165260356 151742635 0 0 3806568 2653463 307154607 255027743 7888382 7199228 0 0 875000 875000 0 0 0 0 7000000 7000000 0 0 0 0 41871834 37739542 57635216 52813770 X 241029023 194119787 8490368 8094186 249519391 202213973 307154607 255027743 X -19240715 -28064703 X false true X true false X MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK NY UNIVERSITY OF TEXAS MD ANDERSON CANCER CENT HOUSTON TX STANFORD MEDICINE STANFORD CA UNIVERSITY OF CALIFORNIA LOS ANGELES LOS ANGELES CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO CA UNIVERSITY OF PENNSYLVANIA PHILADELPHIA PA DANA-FARBER CANCER INSTITUTE BOSTON MA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI NEW YORK NY FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA WASHINGTON UNIVERSITY IN ST LOUIS ST LOUIS MO WEILL CORNELL MEDICINE NEW YORK NY BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE DUARTE CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 720271 720271 0 0 8241252 7986252 255000 255000 GEORGIAMUNE INC. 19999996 F APRICITY HEALTH, LLC 232281 F SENTI BIOSCIENCES, INC. 165000 F 3T BIOSCIENCES, INC. 1530855 F TCELERON 220000 F CARGO THERAPEUTICS, INC. 560855 F SPOTLIGHT 622600 F 23331587 IMAGINAB 1004281 F MOONLIGHT BIO 4700000 F LYELL IMMUNOPHARMA,INC 14132441 F ARSENAL BIOSCIENCES 53620874 F AFFINI-T THERAPEUTICS 20008371 F 3T BIOSCIENCES 3104167 F DISPATCH BIO 39772501 F AKAMIS 10400000 F TWAIN 5000000 F 151742635 0 CONDITIONAL CONTRIBUTIONS 35000000 LEASE LIABILITY 2739542 37739542 X -4402067 -28064703 -28064703 23662636 23662636 42903351 42903351 42903351 PART X, LINE 2: PICI HAS NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES AS OF DECEMBER 31, 2023 AND 2022. true Europe (Including Iceland and Greenland) 0 0 Program Services SERVICES&SPONSORSHIPS 22615 Europe (Including Iceland and Greenland) 0 0 Investments 10400000 East Asia and the Pacific 0 0 Program Services RESEARCH SERVICES 2000 East Asia and the Pacific 0 0 Investments 5000000 0 0 0 0 15424615 15424615 false false true false false false PART I, LINE 2 PICI AWARDS GRANTS SUBJECT TO A MASTER COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. EACH INSTITUTION SUBMITS PROJECT PROPOSALS WHICH ARE EVALUATED TO ENSURE THEY ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. NO FOREIGN GRANTS WERE MADE IN 2023. PART I, LINE 3, NUMBERS (2) AND (4) EACH OF THESE INVESTMENTS ARE PROGRAM-RELATED INVESTMENTS OF PICI. PICI INVESTS IN COMPANIES TO ACCELERATE FACILITATING THE DEVELOPMENT OF NOVEL CANCER THERAPIES. EACH INVESTMENT COMPANY MUST PROVIDE QUARTERLY FINANCIALS AND PICI IS REPRESENTED ON THE BOARD OF DIRECTORS FOR ONE OF THE INVESTMENTS. RESEARCH SPONSORSHIP WAS ALIGNED WITH THE COMPANY MISSION AND THE REMAINING IMMATERIAL SPEND WAS WITH VENDORS TO SUPPORT CLINICAL TRIALS AND EMPLOYEE DEVELOPMENT. PART I, LINE 3 ACCRUAL BASIS true BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE 1500 E DUARTE ROADE DUARTE CA 91010 953435919 501(C)(3) 333333 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY CHILDREN'S HOSPITAL OF PHILADELPHIA 3401 CIVIC CENTER PHILADELPHIA PA 19104 232237932 501(C)(3) 360000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY FHCRC - HUTCHINSON 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 528249 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY ICAHN SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 203737 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE BOX 69 NEW YORK NY 10065 912154267 501(C)(3) 278726 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 2947554 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA 10920 WILSHIRE BLVD LOS ANGELES CA 90024 956006143 GOVT 304336 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 GOVT 5003730 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVE SAINT LOUIS MO 63112 430653611 GOVT 623479 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE J DAVID GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501(C)(3) 2644109 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCI 333 CALIFORNIA ST SAN FRANCISCO CA 94143 946036493 GOVT 614626 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA LOS ANGELES CA 900898001 951642394 501(C)(3) 125124 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY 12 0 PART I, LINE 2: PICI AWARDS GRANTS SUBJECT TO A MAIN COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. PICI AND EACH INSTITUTION JOINTLY REVIEW AND APPROVE PROJECT PROPOSALS TO ENSURE THEY HAVE A LEGITIMATE RESEARCH PURPOSE AND ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. X X true true X X X X false false false false false false false true false UTE DUGAN MD CHIEF MEDICAL OFFICER 606786 0 181200 0 1170 0 9900 0 45167 0 844223 0 0 0 JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 586695 0 175900 0 1170 0 8750 0 44999 0 817514 0 0 0 TARAK MODY CHIEF BUSINESS OFFICER 471990 0 141800 0 1170 0 9900 0 44999 0 669859 0 0 0 KEVIN MARKS CHIEF LEGAL OFFICER 429103 0 129100 0 1170 0 69900 0 44999 0 674272 0 0 0 SARA COBLIN SR VP FINANCE & ADMIN. 420874 0 126000 0 1170 0 9900 0 28746 0 586690 0 0 0 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 420270 0 126000 0 1170 0 9900 0 31386 0 588726 0 0 0 MARKO SPASIC SR MEDICAL DIR, HEAD OF MED 367670 0 107440 0 1170 0 0 0 15180 0 491460 0 0 0 CHRIS CABANSKI SR DIR, NETWORK CLINICAL RES. 275392 0 79380 0 1095 0 9806 0 31528 0 397201 0 0 0 PART I, LINE 1A ANYONE TRAVELING OVER 3000 MILES CAN FLY BUSINESS CLASS OR FIRST CLASS (IF ONLY 2 LEVELS OF SERVICE ARE OFFERED). VP'S CAN TRAVEL BUSINESS OR FIRST CLASS FOR TRAVEL OVER 2000 MILES. PART I, LINE 3 THE CHIEF EXECUTIVE OFFICER POSITION WAS VACANT DURING 2023. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES IN DETERMINING SUCH COMPENSATION: THE BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE REVIEWS ANY PROPOSED COMPENSATION, INCLUDING THE SALARY, OF ITS CHIEF EXECUTIVE OFFICER TO ENSURE THAT, IN EACH CASE, SUCH SALARY IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. PART I, LINE 7 MOST OF PICI'S EMPLOYMENT AGREEMENTS, WHICH ARE NEGOTIATED AT ARMS-LENGTH WITH REFERENCE TO COMPARABILITY DATA, CONTAIN A PROVISION PERMITTING ANNUAL INCENTIVE BONUSES, WHICH ARE CAPPED AT UP TO A FIXED PERCENTAGE. SEAN PARKER CHAIR OF THE BOARD & DIRECTOR OPERATING SUPPORT X 7000000 7000000 false true true JOHN CONNOLLY PHD KEY EMPLOYEE HOME LOAN X 750000 764842 false true true 7764842 PART II THIS LOAN WAS MADE BY MR. PARKER TO PICI TO ALLOW PICI TO FURTHER ITS TAX-EXEMPT ACTIVITIES. FORM 990, PART I, LINE 1 DESCRIPTION OF ORGANIZATION MISSION: THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) IS A SAN FRANCISCO-BASED NONPROFIT WHICH HAS ESTABLISHED COLLABORATION BETWEEN THE COUNTRY'S LEADING IMMUNOTHERAPY RESEARCHERS AND CANCER CENTERS, INCLUDING STANFORD UNIVERSITY; THE UNIVERSITY OF CALIFORNIA, LOS ANGELES; THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO; THE UNIVERSITY OF PENNSYLVANIA; DANA FARBER CANCER INSTITUTE; AND GLADSTONE INSTITUTES. PICI ALSO SUPPORTS TOP RESEARCHERS AT OTHER INSTITUTIONS, INCLUDING CITY OF HOPE; FRED HUTCHINSON CANCER RESEARCH CENTER; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; INSTITUTE FOR SYSTEMS BIOLOGY; MEMORIAL SLOAN KETTERING CANCER CENTER; THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER; WEILL CORNELL MEDICAL COLLEGE; AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS. BY FORGING ALLIANCES WITH ACADEMIC, INDUSTRY, AND NONPROFIT PARTNERS PICI SUPPORTS NOVEL RESEARCH TO FULFILL ITS MISSION: TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TRANSFORM ALL CANCERS INTO CURABLE DISEASES. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS IS COMPRISED OF ONE 'CLASS A' DIRECTOR WITH THE BALANCE OF THE DIRECTORS SERVING AS 'CLASS B' DIRECTORS. THE CLASS A DIRECTOR MUST BE PRESENT TO CONSTITUTE A QUORUM, UNLESS THE CLASS A DIRECTOR'S RECUSAL IS REQUIRED BY LAW OR CORPORATE POLICY. EACH DIRECTOR IS ENTITLED TO ONE VOTE. ANY ACT OF THE BOARD OF DIRECTORS REQUIRES THE AFFIRMATIVE VOTE OF BOTH THE CLASS A DIRECTOR AND A MAJORITY OF THE CLASS B DIRECTORS PRESENT AT A MEETING AT WHICH A QUORUM IS PRESENT, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS. PICI DOES HAVE AN EXECUTIVE COMMITTEE. IT HAS ALL THE AUTHORITY OF THE BOARD OF DIRECTORS BETWEEN REGULAR AND SPECIAL MEETINGS, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS OR BY THE BOARD OF DIRECTORS IN SPECIFIC INSTANCES. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO AND REVIEWED BY THE BOARD OF DIRECTORS AT ITS NEXT REGULARLY SCHEDULED MEETING. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS HAVE A BUSINESS RELATIONSHIP AND/OR FAMILY RELATIONSHIP: JEFFREY BLUESTONE, JOHN CONNOLLY, SUSAN DAWSON, ERIC ESRAILIAN, SCOTT GOTTLIEB, BEN HOROWITZ, JEFF HUBER, REED JOBS, BOB NELSEN, BRUCE PARKER, SEAN PARKER, BOB PITTMAN, MICHAEL POLANSKY, TOM VAN LOBEN SELS. FORM 990, PART VI, SECTION A, LINE 7A THE DESIGNATOR HAS THE AUTHORITY TO APPOINT MEMBERS OF PICI'S GOVERNING BODY. FORM 990, PART VI, SECTION A, LINE 7B THE DESIGNATOR HAS THE AUTHORITY TO REMOVE MEMBERS OF PICI'S GOVERNING BODY, TO CONSENT TO SUCH REMOVAL BY THE BOARD, AND TO CONSENT TO ANY AMENDMENTS TO PICI'S BYLAWS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD AUTHORIZES AND OVERSEES A REVIEW OF THE ADMINISTRATION OF THE CONFLICT OF INTEREST POLICY. THE REVIEW CONSIDERS THE LEVEL OF COMPLIANCE WITH THE POLICY, THE CONTINUING SUITABILITY OF THE POLICY, AND WHETHER THE POLICY SHOULD BE MODIFIED AND IMPROVED. IF A TRANSACTION ARISES WHERE THERE IS A CONFLICT OF INTEREST, THE PERSON WITH SUCH CONFLICT IS NOT ALLOWED TO VOTE ON THE TRANSACTION NOR BE PRESENT FOR SUCH VOTE. THE CONFLICT OF INTEREST POLICY COVERS EACH DIRECTOR, CORPORATE OFFICER, TOP MANAGEMENT OFFICIAL, TOP FINANCIAL OFFICIAL AND EACH KEY EMPLOYEE OF PICI, AND OTHERS THAT PICI MAY IDENTIFY. FORM 990, PART VI, SECTION B, LINE 15 FORM 990, PART VI, SECTION B, LINE 15A - AS STATED AT SCHEDULE J, PART I, LINE 3, THE CEO POSITION WAS VACANT DURING THE 2023 CALENDAR YEAR. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES: THE BOARD OF DIRECTORS APPROVES THE SALARY OF PICI'S CHIEF EXECUTIVE OFFICER ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. FORM 990, PART VI, SECTION B, LINE 15B THE ORGANIZATION DOES NOT COMPENSATE ITS CORPORATE OFFICERS, BUT ADHERES TO THE FOLLOWING PROCEDURES FOR ITS KEY EMPLOYEES: THE BOARD OF DIRECTORS (OR DULY AUTHORIZED AND INDEPENDENT BOARD COMMITTEE) APPROVES THE SALARY OF PICI'S KEY EMPLOYEES ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATION ORGANIZATIONS. FOR ITS OTHER EMPLOYEES, PICI WORKS WITH A RECRUITER AND, AS PART OF THAT PROCESS, ROUTINELY COMPARES THE PROPOSED SALARY WITH SALARIES PAID BY OTHER ORGANIZATIONS FOR SIMILAR POSITIONS. FORM 990, PART VI, SECTION C, LINE 19 PICI'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE AS REQUIRED BY LAW. MAVERIC LLC 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 853467441 COVID-19 CLIN CA 0 PICI SEAN N PARKER FOUNDATION 314 LYTTON AVE PALTO ALTO CA 94301 274389819 NONPROFIT SUP CA 501(C)(3) PF NA true ECONOMIC INNOVATION GROUP INC 616 H STREET NW SUITE 550 WASHINGTON DC 20001 462450336 PUBLIC INTERE DC 501(C)(4) N/A NA true false false false false false false false false false false false false false false false false false false false PART I, IDENTIFICATION OF DISREGARDED ENTITIES: NAME OF DISREGARDED ENTITY: MAVERIC, LLC ADDRESS: 1 LETTERMAN DRIVE, D3500 SAN FRANCISCO, CA 94129 EIN: 85-3467441 PRIMARY ACTIVITY: COVID-19 CLINICAL TRIAL MANAGEMENT (CURRENTLY INACTIVE) DIRECT CONTROLLING ENTITY: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY SCHEDULE R, SUPPLEMENTAL INFORMATION: THE CLASS A DIRECTOR ALSO HAS A CONTROLLING INTEREST IN SEVERAL PASSIVE INVESTMENT VEHICLES. THESE INVESTMENT VEHICLES AND THE TAX-EXEMPT ENTITIES DISCLOSED UNDER PART II ABOVE MAY TECHNICALLY BE CONSIDERED "RELATED ORGANIZATIONS" OF PICI FOR IRS FORM 990 REPORTING PURPOSES THROUGH THEIR RELATIONSHIP WITH THE CLASS A DIRECTOR. THE PASSIVE INVESTMENT VEHICLES HAVE NO TRANSACTIONS OR BUSINESS RELATIONSHIPS WITH PICI AND ARE NOT DISCLOSED ON SCHEDULE R.